Drugs That Prolong The Qt Interval + Nipocalimab Interaction
Moderateinteraction on record
Description
Concomitant use may lower systemic exposures and reduce effectiveness. Closely monitor for reduced effectiveness; consider discontinuing IMAAVY.
Mechanism
Competition for human neonatal Fc receptor (FcRn) binding
Source: NLP:nipocalimab